Results 161 to 170 of about 6,879 (203)
Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients With Dyslipidemia
BACKGROUND: Rimonabant, a selective cannabinoid-1 receptor (CB1) blocker, has been shown to reduce body weight and improve cardiovascular risk factors in obese patients.
Jean-Pierre Després +2 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs, 2006
Rimonabant is the first of a new class of selective cannabinoid receptor-1 blockers. It reduces the overactivity of the endocannabinoid system, improving lipid and glucose metabolism and regulating food intake and energy balance. In four randomised, double-blind clinical trials in overweight or obese adults with or without type 2 diabetes and/or ...
Sheridan, Henness +2 more
+6 more sources
Rimonabant is the first of a new class of selective cannabinoid receptor-1 blockers. It reduces the overactivity of the endocannabinoid system, improving lipid and glucose metabolism and regulating food intake and energy balance. In four randomised, double-blind clinical trials in overweight or obese adults with or without type 2 diabetes and/or ...
Sheridan, Henness +2 more
+6 more sources
Depression and Anxiety With Rimonabant
Lancet, The, 2007Philip B. Mitchell, Margaret J Morris
exaly +3 more sources
Rimonabant for overweight or obesity
Cochrane Database of Systematic Reviews, 2006Worldwide, the prevalence of obesity and overweight in industrialized countries and in a substantial number of developing countries is increasing at an alarming rate. Rimonabant is a selective cannabinoid-1 receptor antagonist that has been investigated for its efficacy in reducing body weight and associated risk factors in obese people.
C, Curioni, C, André
openaire +2 more sources
Rimonabant for the Treatment of Obesity
Recent Patents on Cardiovascular Drug Discovery, 2008Obesity is a growing public health problem that is already reaching epidemic proportions and is increasingly encompassing young children and adolescents. Despite the increasing prevalence and the health risks associated with obesity, the pharmacotherapeutic options for treating obesity are limited. The endogenous cannabinoid or endocan-nabinoid system (
Ashish, Samat +3 more
openaire +2 more sources
Rimonabant—A Selective CB1 Antagonist
Annals of Pharmacotherapy, 2005OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy, and safety of rimonabant, a new selective cannabinoid receptor antagonist. DATA SOURCES: Primary literature and review articles were obtained via a MEDLINE ...
Steven Thomas, Boyd +1 more
openaire +2 more sources
Rimonabant in Obese Patients With Type 2 Diabetes
Lancet, The, 2007Dominique Roberfroid
exaly +6 more sources
Effect of Rimonabant on Weight Reduction and Cardiovascular Risk
Lancet, The, 2005Bob W van Oosten
exaly +6 more sources

